Compare BioNano Genomics Inc (BNGO) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Fortinet Inc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Fortinet Inc trades at $168.18 (market cap $122.23B). The key difference: Fortinet Inc is far larger — about 9259.8× BioNano Genomics Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | FTNT | |
|---|---|---|
Market Cap | $13.20M | $122.23B |
Sector | Health | Technology |
52-Week High | $4.92 | $166.83 |
52-Week Low | $1.09 | $74.39 |
Enterprise Value | $15.81M | $119.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Fortinet (FTNT) trades at $160.62, up 1.97% on the day, with strong technical momentum and bullish moving averages. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.82 exceeding the $0.619 estimate. Revenue growth remains solid, reaching $6.80B in 2025, while high valuation ratios like a P/E of 62.26 reflect premium investor expectations. Recent news highlights expansion in AI-driven security solutions, positioning FTNT to capitalize on rising cybersecurity demand.
The outlook for FTNT is positive, driven by sustained demand for cybersecurity and AI integration, though elevated valuations and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, but the average price target of $121.11 suggests caution relative to the current price. Investors should monitor execution against raised 2026 guidance and industry spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
